xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT05995964</url>
    </required_header>
    <id_info>
      <org_study_id>C4531002</org_study_id>
      <nct_id>NCT05995964</nct_id>
    </id_info>
    <brief_title>A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis</brief_title>
    <official_title>A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF-07275315 AND PF-07264660 IN ADULT PARTICIPANTS WITH MODERATE-SEVERE ATOPIC DERMATITIS</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>Pfizer</agency>
        <agency_class>Industry</agency_class>
      </lead_sponsor>
    </sponsors>
    <source>Pfizer</source>
    <oversight_info>
      <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        The purpose of this study is to learn about the safety and effects of 2 study medicines&#xD;
        (PF-07275315 and PF-07264660) for the treatment of atopic dermatitis (AD). AD is a long-&#xD;
        lasting itchy red rash, caused by a skin reaction.&#xD;
  &#xD;
        This study is seeking participants who:&#xD;
  &#xD;
          -  are 18 years of age or more.&#xD;
  &#xD;
          -  Were confirmed to have AD at least 6 months ago.&#xD;
  &#xD;
          -  Are not having an effective treatment result from medicines that are applied on skin for&#xD;
             AD.&#xD;
  &#xD;
          -  Are considered by their doctors to have moderate to severe AD.&#xD;
  &#xD;
        All participants in the study will receive either PF-07275315 or PF-07264660 or placebo. A&#xD;
        placebo does not have any medicine in it but looks just like the medicines being studied.&#xD;
  &#xD;
        PF-07275315 or PF-07264660 or placebo will be given as multiple shots in the clinic over the&#xD;
        course of 12 weeks.&#xD;
  &#xD;
        Stage 1 participants will receive shots at the study clinic on Day 1, Week 1, Week 2, Week 4,&#xD;
        Week 6, Week 8, Week 10 and Week 12.&#xD;
  &#xD;
        Stage 2 participants will receive shots at the study clinic on Day 1, Week 4, Week 8 and Week&#xD;
        12.&#xD;
  &#xD;
        The experiences of people receiving PF-07275315 or PF-07264660 will be compared to people who&#xD;
        do not. This will help determine if PF-07275315 and PF-07264660 are safe and effective.&#xD;
  &#xD;
        Participants will be involved in this study for up to 80 weeks (20 months). During this time,&#xD;
        Stage 1 participants will have 16 visits at the study clinic, and Stage 2 participants will&#xD;
        have 12 visits at the study clinic.&#xD;
      </textblock>
    </brief_summary>
    <overall_status>Recruiting</overall_status>
    <start_date type="Actual">August 22, 2023</start_date>
    <completion_date type="Anticipated">April 6, 2026</completion_date>
    <primary_completion_date type="Anticipated">April 6, 2026</primary_completion_date>
    <phase>Phase 2</phase>
    <study_type>Interventional</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <allocation>Randomized</allocation>
      <intervention_model>Parallel Assignment</intervention_model>
      <primary_purpose>Treatment</primary_purpose>
      <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    </study_design_info>
    <primary_outcome>
      <measure>The number of participants achieving ≥75% improvement in EAS175 from baseline at week16.</measure>
      <time_frame>Week 16</time_frame>
      <description>EASI75 (≥75% improvement from baseline) at Week 16</description>
    </primary_outcome>
    <secondary_outcome>
      <measure>The number and % of participants achieving IGA score of clear (0) or almost clear (1) (on a 5-point scale) and a reduction from baseline of ≥2 points at all scheduled time points</measure>
      <time_frame>Screening through study completion, an average of 76 weeks.</time_frame>
      <description>IGA score of clear (0) or almost clear (1) (on a 5-point scale) and a reduction from baseline of ≥2 points at all scheduled time points</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>The number and % of participants achieving EASI75 (≥75% improvement from baseline) at scheduled time points except Week 16</measure>
      <time_frame>All scheduled timepoints other than Week 16, screening through study completion, an average of 76 weeks.</time_frame>
      <description>EASI75 (≥75% improvement from baseline) at scheduled time points except Week 16</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>The number and % of participants achieving a Percent change from baseline in EASI total score at scheduled time points</measure>
      <time_frame>Screening through study completion, an average of 76 weeks.</time_frame>
      <description>Percent change from baseline in EASI total score at scheduled time points</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>The number and % of participants with treatment emergent AEs</measure>
      <time_frame>Screening - Week 76</time_frame>
      <description>Incidence of treatment emergent AEs</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>The number and % of participants with clinically significant changes in vital signs</measure>
      <time_frame>Screening - Week 76</time_frame>
      <description>Incidence of clinically significant changes in vital signs</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>The number and % of participants with clinically significant changes in ECG</measure>
      <time_frame>Screening - Week 76</time_frame>
      <description>Incidence of clinically significant changes in ECG</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>The number and % of participants with clinically significant changes in laboratory tests</measure>
      <time_frame>Screening - Week 76</time_frame>
      <description>Incidence of clinically significant changes in laboratory tests</description>
    </secondary_outcome>
    <number_of_arms>8</number_of_arms>
    <enrollment type="Anticipated">340</enrollment>
    <condition>Atopic Dermatitis</condition>
    <arm_group>
      <arm_group_label>Stage 1_PF-07275315</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Stage 1 PF-07275315 Injections on Day 1, Week 1, Week 2, Week 4, Week 6, Week 8, Week 10 and Week 12.</description>
    </arm_group>
    <arm_group>
      <arm_group_label>Stage 1_PF-07264660</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Stage 1 PF-07264660 Injections on Day 1, Week 1, Week 2, Week 4, Week 6, Week 8, Week 10 and Week 12.</description>
    </arm_group>
    <arm_group>
      <arm_group_label>Stage 1_Placebo</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Stage 1 Placebo Injections on Day 1, Week 1, Week 2, Week 4, Week 6, Week 8, Week 10 and Week 12.</description>
    </arm_group>
    <arm_group>
      <arm_group_label>Stage 2_PF-07275315 or PF-07264660_Dose A</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Stage 2 PF-07275315 or PF-07264660 Injections on Day 1, Week 4, Week 8 and Week 12.</description>
    </arm_group>
    <arm_group>
      <arm_group_label>Stage 2_PF-07275315 or PF-07264660_Dose B</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Stage 2 PF-07275315 or PF-07264660 Injections on Day 1, Week 4, Week 8 and Week 12.</description>
    </arm_group>
    <arm_group>
      <arm_group_label>Stage 2_PF-07275315 or PF-07264660_Dose C</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Stage 2 PF-07275315 or PF-07264660 Injections on Day 1, Week 4, Week 8 and Week 12.</description>
    </arm_group>
    <arm_group>
      <arm_group_label>Stage 2_PF-07275315 or PF-07264660_Dose D</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Stage 2 PF-07275315 or PF-07264660 Injections on Day 1, Week 4, Week 8 and Week 12.</description>
    </arm_group>
    <arm_group>
      <arm_group_label>Stage 2_Placebo</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Stage 2 Placebo Injections on Day 1, Week 4, Week 8 and Week 12.</description>
    </arm_group>
    <intervention>
      <intervention_type>Drug</intervention_type>
      <intervention_name>PF-07275315</intervention_name>
      <description>subcutaneous injection</description>
      <arm_group_label>Stage 1_PF-07275315</arm_group_label>
      <arm_group_label>Stage 2_PF-07275315 or PF-07264660_Dose A</arm_group_label>
      <arm_group_label>Stage 2_PF-07275315 or PF-07264660_Dose B</arm_group_label>
      <arm_group_label>Stage 2_PF-07275315 or PF-07264660_Dose C</arm_group_label>
      <arm_group_label>Stage 2_PF-07275315 or PF-07264660_Dose D</arm_group_label>
    </intervention>
    <intervention>
      <intervention_type>Drug</intervention_type>
      <intervention_name>PF-07264660</intervention_name>
      <description>subcutaneous injection</description>
      <arm_group_label>Stage 1_PF-07264660</arm_group_label>
      <arm_group_label>Stage 2_PF-07275315 or PF-07264660_Dose A</arm_group_label>
      <arm_group_label>Stage 2_PF-07275315 or PF-07264660_Dose B</arm_group_label>
      <arm_group_label>Stage 2_PF-07275315 or PF-07264660_Dose C</arm_group_label>
      <arm_group_label>Stage 2_PF-07275315 or PF-07264660_Dose D</arm_group_label>
    </intervention>
    <intervention>
      <intervention_type>Other</intervention_type>
      <intervention_name>Placebo</intervention_name>
      <description>subcutaneous injection</description>
      <arm_group_label>Stage 1_Placebo</arm_group_label>
      <arm_group_label>Stage 2_Placebo</arm_group_label>
    </intervention>
    <eligibility>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
          Must meet the following AD criteria:&#xD;
  &#xD;
            1. Clinical diagnosis of chronic atopic dermatitis for at least 6 months prior to Day 1;&#xD;
  &#xD;
            2. Either an inadequate response to treatment with topical medications (for at least 4&#xD;
               consecutive weeks within 1 year of the first dose of the study intervention); OR&#xD;
               documented reason why topical treatments are considered medically inappropriate;&#xD;
  &#xD;
            3. Moderate to severe AD (defined as having an affected BSA (captured as part of EASI)&#xD;
               ≥10%, IGA ≥3, and EASI ≥16 at both the screening and baseline visits).&#xD;
  &#xD;
               Other Inclusion Criteria:&#xD;
  &#xD;
            4. BMI of 17.5 to 40 kg/m2; and a total body weight &gt;45 kg (100 lbs).&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
          - Medical Conditions:&#xD;
  &#xD;
            1. Significant allergic or autoimmune diseases, other than AD and well controlled mild to&#xD;
               moderate including but not limited to: SLE or other complement disorders; Type 1&#xD;
               diabetes; Irritable bowel syndrome; Multiple Sclerosis.&#xD;
  &#xD;
            2. History of significant allergic reactions, including anaphylaxis and reactions to&#xD;
               protein therapeutics, except to single, identified, avoidable allergens (eg, peanut&#xD;
               allergy).&#xD;
  &#xD;
            3. Any of the following acute or chronic infections or infection history:&#xD;
  &#xD;
                 1. Active infection (including helminth or parasitic) requiring treatment within 2&#xD;
                    weeks prior to the screening;&#xD;
  &#xD;
                 2. Infection requiring hospitalization or systemic (eg, parenteral, oral)&#xD;
                    antimicrobial therapy within 60 days prior to Day 1;&#xD;
  &#xD;
                 3. Active chronic or acute skin infection requiring treatment with systemic&#xD;
                    antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 2&#xD;
                    weeks prior to Day 1, or superficial skin infections within 1 week prior to Day&#xD;
                    1.&#xD;
  &#xD;
                 4. Any infection judged to be an opportunistic infection or clinically significant&#xD;
                    by the investigator, within 6 months prior to Day 1;&#xD;
  &#xD;
            4. History of or current evidence of inflammatory skin conditions (eg, psoriasis,&#xD;
               seborrheic dermatitis, lupus) at the time of Day 1 that would interfere with&#xD;
               evaluation of AD or response to treatment.&#xD;
  &#xD;
            5. Any medical or psychiatric condition including recent (within the past year) or active&#xD;
               suicidal ideation/behavior or laboratory abnormality that may increase the risk of&#xD;
               study participation or, in the investigator's judgment, make the participant&#xD;
               inappropriate for the study.&#xD;
  &#xD;
               - Prior/Concomitant Therapy:&#xD;
  &#xD;
            6. Current use of any prohibited concomitant medication(s).&#xD;
  &#xD;
            7. Phototherapy narrowband UVB (NB UVB) or broadband phototherapy or regular use (more&#xD;
               than 2 visits per week) of a tanning booth/parlor within 4 weeks prior to Day 1.&#xD;
  &#xD;
               - Prior/Concurrent Clinical Study Experience:&#xD;
  &#xD;
            8. Previous administration with an investigational product (drug or vaccine) within 30&#xD;
               days (or as determined by the local requirement) or 5 half lives preceding the first&#xD;
               dose of study intervention used in this study (whichever is longer).&#xD;
  &#xD;
            9. HIV infection, or infection with hepatitis B or hepatitis C viruses according to&#xD;
               protocol-specific testing algorithm.&#xD;
  &#xD;
           10. Evidence of active or latent TB, or inadequately treated infection with Mycobacterium&#xD;
               TB. A participant who is currently being treated for active or latent TB infection&#xD;
               must be excluded from this study.&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>18 Years</minimum_age>
      <maximum_age>N/A</maximum_age>
      <healthy_volunteers>No</healthy_volunteers>
    </eligibility>
    <overall_official>
      <last_name>Pfizer CT.gov Call Center</last_name>
      <role>Study Director</role>
      <affiliation>Pfizer</affiliation>
    </overall_official>
    <overall_contact>
      <last_name>Pfizer CT.gov Call Center</last_name>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </overall_contact>
    <location>
      <facility>
        <name>Marvel Clinical Research</name>
        <address>
          <city>Huntington Beach</city>
          <state>California</state>
          <zip>92647</zip>
          <country>United States</country>
        </address>
      </facility>
      <status>Recruiting</status>
    </location>
    <location>
      <facility>
        <name>Renaissance Research and Medical Group</name>
        <address>
          <city>Cape Coral</city>
          <state>Florida</state>
          <zip>33991</zip>
          <country>United States</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
    </location>
    <location>
      <facility>
        <name>Florida International Medical Research</name>
        <address>
          <city>Coral Gables</city>
          <state>Florida</state>
          <zip>33134</zip>
          <country>United States</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
    </location>
    <location>
      <facility>
        <name>Revival Research</name>
        <address>
          <city>Doral</city>
          <state>Florida</state>
          <zip>33122</zip>
          <country>United States</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
    </location>
    <location>
      <facility>
        <name>Global Health Research Center, Inc.</name>
        <address>
          <city>Miami Lakes</city>
          <state>Florida</state>
          <zip>33016</zip>
          <country>United States</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
    </location>
    <location>
      <facility>
        <name>SouthCoast Research Center</name>
        <address>
          <city>Miami</city>
          <state>Florida</state>
          <zip>33136</zip>
          <country>United States</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
    </location>
    <location>
      <facility>
        <name>Floridian Research Institute</name>
        <address>
          <city>Miami</city>
          <state>Florida</state>
          <zip>33179</zip>
          <country>United States</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
    </location>
    <location>
      <facility>
        <name>Clinical Neuroscience Solutions, Inc.</name>
        <address>
          <city>Orlando</city>
          <state>Florida</state>
          <zip>32801</zip>
          <country>United States</country>
        </address>
      </facility>
      <status>Recruiting</status>
    </location>
    <location>
      <facility>
        <name>Southern Indiana Clinical Trials</name>
        <address>
          <city>New Albany</city>
          <state>Indiana</state>
          <zip>47150</zip>
          <country>United States</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
    </location>
    <location>
      <facility>
        <name>Maryland Laser Skin and Vein</name>
        <address>
          <city>Hunt Valley</city>
          <state>Maryland</state>
          <zip>21030</zip>
          <country>United States</country>
        </address>
      </facility>
      <status>Recruiting</status>
    </location>
    <location>
      <facility>
        <name>Michigan Center for Research Company</name>
        <address>
          <city>Clarkston</city>
          <state>Michigan</state>
          <zip>48346</zip>
          <country>United States</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
    </location>
    <location>
      <facility>
        <name>Clinical Neuroscience Solutions Inc.</name>
        <address>
          <city>Memphis</city>
          <state>Tennessee</state>
          <zip>38119</zip>
          <country>United States</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
    </location>
    <location>
      <facility>
        <name>North Texas Center for Clinical Research</name>
        <address>
          <city>Frisco</city>
          <state>Texas</state>
          <zip>75034</zip>
          <country>United States</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
    </location>
    <location>
      <facility>
        <name>Complete Dermatology</name>
        <address>
          <city>Sugar Land</city>
          <state>Texas</state>
          <zip>77479</zip>
          <country>United States</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
    </location>
    <location>
      <facility>
        <name>Virginia Dermatology and Skin Cancer Center</name>
        <address>
          <city>Norfolk</city>
          <state>Virginia</state>
          <zip>23502</zip>
          <country>United States</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
    </location>
    <location_countries>
      <country>United States</country>
    </location_countries>
    <link>
      <url>https://pmiform.com/clinical-trial-info-request?StudyID=C4531002</url>
      <description>To obtain contact information for a study center near you, click here.</description>
    </link>
    <verification_date>September 2023</verification_date>
    <study_first_submitted>July 26, 2023</study_first_submitted>
    <study_first_submitted_qc>August 10, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">August 16, 2023</study_first_posted>
    <last_update_submitted>September 14, 2023</last_update_submitted>
    <last_update_submitted_qc>September 14, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">September 15, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Sponsor</responsible_party_type>
    </responsible_party>
    <keyword>Eczema</keyword>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Dermatitis, Atopic</mesh_term>
      <mesh_term>Dermatitis</mesh_term>
      <mesh_term>Eczema</mesh_term>
    </condition_browse>
    <patient_data>
      <sharing_ipd>Yes</sharing_ipd>
      <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
      <ipd_url>https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests</ipd_url>
    </patient_data>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT05995964
  org study id: C4531002
  nct id: NCT05995964
  lead sponsor: 
  is fda regulated drug: Yes
  is fda regulated device: No
  The purpose of this study is to learn about the safety and effects of 2 study medicines
        (PF-07275315 and PF-07264660) for the treatment of atopic dermatitis (AD). AD is a long-
        lasting itchy red rash, caused by a skin reaction.
  
        This study is seeking participants who:
  
          -  are 18 years of age or more.
  
          -  Were confirmed to have AD at least 6 months ago.
  
          -  Are not having an effective treatment result from medicines that are applied on skin for
             AD.
  
          -  Are considered by their doctors to have moderate to severe AD.
  
        All participants in the study will receive either PF-07275315 or PF-07264660 or placebo. A
        placebo does not have any medicine in it but looks just like the medicines being studied.
  
        PF-07275315 or PF-07264660 or placebo will be given as multiple shots in the clinic over the
        course of 12 weeks.
  
        Stage 1 participants will receive shots at the study clinic on Day 1, Week 1, Week 2, Week 4,
        Week 6, Week 8, Week 10 and Week 12.
  
        Stage 2 participants will receive shots at the study clinic on Day 1, Week 4, Week 8 and Week
        12.
  
        The experiences of people receiving PF-07275315 or PF-07264660 will be compared to people who
        do not. This will help determine if PF-07275315 and PF-07264660 are safe and effective.
  
        Participants will be involved in this study for up to 80 weeks (20 months). During this time,
        Stage 1 participants will have 16 visits at the study clinic, and Stage 2 participants will
        have 12 visits at the study clinic.
  allocation: Randomized
  intervention model: Parallel Assignment
  primary purpose: Treatment
  masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  measure: The number of participants achieving ≥75% improvement in EAS175 from baseline at week16.
  time frame: Week 16
  description: EASI75 (≥75% improvement from baseline) at Week 16
  measure: The number and % of participants achieving IGA score of clear (0) or almost clear (1) (on a 5-point scale) and a reduction from baseline of ≥2 points at all scheduled time points
  time frame: Screening through study completion, an average of 76 weeks.
  description: IGA score of clear (0) or almost clear (1) (on a 5-point scale) and a reduction from baseline of ≥2 points at all scheduled time points
  measure: The number and % of participants achieving EASI75 (≥75% improvement from baseline) at scheduled time points except Week 16
  time frame: All scheduled timepoints other than Week 16, screening through study completion, an average of 76 weeks.
  description: EASI75 (≥75% improvement from baseline) at scheduled time points except Week 16
  measure: The number and % of participants achieving a Percent change from baseline in EASI total score at scheduled time points
  time frame: Screening through study completion, an average of 76 weeks.
  description: Percent change from baseline in EASI total score at scheduled time points
  measure: The number and % of participants with treatment emergent AEs
  time frame: Screening - Week 76
  description: Incidence of treatment emergent AEs
  measure: The number and % of participants with clinically significant changes in vital signs
  time frame: Screening - Week 76
  description: Incidence of clinically significant changes in vital signs
  measure: The number and % of participants with clinically significant changes in ECG
  time frame: Screening - Week 76
  description: Incidence of clinically significant changes in ECG
  measure: The number and % of participants with clinically significant changes in laboratory tests
  time frame: Screening - Week 76
  description: Incidence of clinically significant changes in laboratory tests
  arm group label: Stage 1_PF-07275315
  arm group type: Experimental
  description: Stage 1 PF-07275315 Injections on Day 1, Week 1, Week 2, Week 4, Week 6, Week 8, Week 10 and Week 12.
  arm group label: Stage 1_PF-07264660
  arm group type: Experimental
  description: Stage 1 PF-07264660 Injections on Day 1, Week 1, Week 2, Week 4, Week 6, Week 8, Week 10 and Week 12.
  arm group label: Stage 1_Placebo
  arm group type: Experimental
  description: Stage 1 Placebo Injections on Day 1, Week 1, Week 2, Week 4, Week 6, Week 8, Week 10 and Week 12.
  arm group label: Stage 2_PF-07275315 or PF-07264660_Dose A
  arm group type: Experimental
  description: Stage 2 PF-07275315 or PF-07264660 Injections on Day 1, Week 4, Week 8 and Week 12.
  arm group label: Stage 2_PF-07275315 or PF-07264660_Dose B
  arm group type: Experimental
  description: Stage 2 PF-07275315 or PF-07264660 Injections on Day 1, Week 4, Week 8 and Week 12.
  arm group label: Stage 2_PF-07275315 or PF-07264660_Dose C
  arm group type: Experimental
  description: Stage 2 PF-07275315 or PF-07264660 Injections on Day 1, Week 4, Week 8 and Week 12.
  arm group label: Stage 2_PF-07275315 or PF-07264660_Dose D
  arm group type: Experimental
  description: Stage 2 PF-07275315 or PF-07264660 Injections on Day 1, Week 4, Week 8 and Week 12.
  arm group label: Stage 2_Placebo
  arm group type: Experimental
  description: Stage 2 Placebo Injections on Day 1, Week 4, Week 8 and Week 12.
  intervention type: Drug
  intervention name: PF-07275315
  description: subcutaneous injection
  arm group label: Stage 1_PF-07275315
  arm group label: Stage 2_PF-07275315 or PF-07264660_Dose A
  arm group label: Stage 2_PF-07275315 or PF-07264660_Dose B
  arm group label: Stage 2_PF-07275315 or PF-07264660_Dose C
  arm group label: Stage 2_PF-07275315 or PF-07264660_Dose D
  intervention type: Drug
  intervention name: PF-07264660
  description: subcutaneous injection
  arm group label: Stage 1_PF-07264660
  arm group label: Stage 2_PF-07275315 or PF-07264660_Dose A
  arm group label: Stage 2_PF-07275315 or PF-07264660_Dose B
  arm group label: Stage 2_PF-07275315 or PF-07264660_Dose C
  arm group label: Stage 2_PF-07275315 or PF-07264660_Dose D
  intervention type: Other
  intervention name: Placebo
  description: subcutaneous injection
  arm group label: Stage 1_Placebo
  arm group label: Stage 2_Placebo
  criteria: 
  gender: All
  minimum age: 18 Years
  maximum age: N/A
  healthy volunteers: No
  last name: Pfizer CT.gov Call Center
  role: Study Director
  affiliation: Pfizer
  last name: Pfizer CT.gov Call Center
  phone: 1-800-718-1021
  email: ClinicalTrials.gov_Inquiries@pfizer.com
  facility: 
  status: Recruiting
  facility: 
  status: Not yet recruiting
  facility: 
  status: Not yet recruiting
  facility: 
  status: Not yet recruiting
  facility: 
  status: Not yet recruiting
  facility: 
  status: Not yet recruiting
  facility: 
  status: Not yet recruiting
  facility: 
  status: Recruiting
  facility: 
  status: Not yet recruiting
  facility: 
  status: Recruiting
  facility: 
  status: Not yet recruiting
  facility: 
  status: Not yet recruiting
  facility: 
  status: Not yet recruiting
  facility: 
  status: Not yet recruiting
  facility: 
  status: Not yet recruiting
  country: United States
  url: https://pmiform.com/clinical-trial-info-request?StudyID=C4531002
  description: To obtain contact information for a study center near you, click here.
  responsible party type: Sponsor
  mesh term: Dermatitis, Atopic
  mesh term: Dermatitis
  mesh term: Eczema
  sharing ipd: Yes
  ipd description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
  ipd url: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests